From Surf Wiki (app.surf) — the open knowledge base
Olsalazine
Pharmaceutical drug used for ulcerative colitis
Pharmaceutical drug used for ulcerative colitis
| Drugs.com =
| elimination_half-life = 0.9 hours
Olsalazine is an anti-inflammatory medication used in the treatment of ulcerative colitis. It is sold under the brand name Dipentum.
Olsalazine itself is a prodrug of mesalazine (5-aminosalicyclic acid or 5-ASA) and is not absorbed in the small intestine. Instead it continues through to the colon where it is cleaved into two molecules of 5-ASA by azoreductases produced by colonic bacteria. Olsalazine thus exerts its anti-inflammatory effect by its colonic breakdown into 5-ASA which inhibits cyclooxygenase and lipoxygenase thereby reducing prostaglandin and leukotriene production.
History
Olsalazine gained Food and Drug Administration (FDA) approval in 1990.
Supply
The drug is supplied by UCB Pharma.
Research
In 2006 the Australian biotech company Giaconda received a European patent for a combination therapy for treating constipation-predominant irritable bowel syndrome that uses olsalazine and the anti-gout drug colchicine, for trials the following year.
References
References
- (6 September 2019). "Olsalazine (Dipentum) Use During Pregnancy".
- (July 1990). "Olsalazine--a further choice in ulcerative colitis". Drug and Therapeutics Bulletin.
- (April 1991). "Olsalazine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in inflammatory bowel disease". Drugs.
- "Olsalazine Sodium 250 mg Capsules - Summary of Product Characteristics (SmPC) - (emc)".
- (28 December 2006). "Giaconda gets European patent for drug". The Sydney Morning Herald.
This article was imported from Wikipedia and is available under the Creative Commons Attribution-ShareAlike 4.0 License. Content has been adapted to SurfDoc format. Original contributors can be found on the article history page.
Ask Mako anything about Olsalazine — get instant answers, deeper analysis, and related topics.
Research with MakoFree with your Surf account
Create a free account to save articles, ask Mako questions, and organize your research.
Sign up freeThis content may have been generated or modified by AI. CloudSurf Software LLC is not responsible for the accuracy, completeness, or reliability of AI-generated content. Always verify important information from primary sources.
Report